However, whether GDF2 is a protective or corrected modifier in certain genetic backgrounds [36,38,39,40] or whether the GDF2 variant leads to PAH by overexpressing the ActR-IIA/IIB-SMAD2/3 signaling route warrants further investigation [36]. The gene discussed is ACVR2A; the disease is pulmonary arterial hypertension.